[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-atherosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-atherosclerosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,85,119,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100324511","coronary-atherosclerosis-t1-weighted-characterization-catch-100324511",false,"NCT03504956","Coronary Atherosclerosis T1-Weighted Characterization (CATCH)","CATCH","Inclusion:\n\n* Healthy Volunteers: male or female ≥ 18 years of age with a BMI\\\u003C30, with no history of cardiovascular disease\n* Patients: Medically stable, male or female ≥ 18 years of age who is have not suspected of having or has been diagnosed with coronary artery disease and undergone stenting or bypass surgery\n\nExclusion:\n\n* Contraindications to MR imaging including mechanically, magnetically, or electrically activated implants, ferromagnetic implants and ferromagnetic foreign bodies, pregnancy.\n* Inability to tolerate MR imaging secondary to an inability to hold breath for a short time or have claustrophobia.\n* Non-compliant with visit instructions, including following procedure instructions\n* Severe allergy to animal dander or animal-instigated asthma\n* Specific to gadolinium-based contrast agents: Renal function test does not meet CSMC standard of care MRI contrast protocol requirements (GFR \\\u003C45ml\u002Fmin) or previous allergic reaction to gadolinium-based contrast agents.\\*\n* Volunteers who have had four or more prior previous gadolinium contrast scan",true,"ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.",[27],"Coronary Atherosclerosis",[29,30],"MRI technique","High Resolution MRI Technique","RECRUITING","2026-08-20",{"date":34,"type":35},"2026-08-21","ACTUAL",{"date":37,"type":35},"2018-07-30",{"date":39,"type":21},"2027-12-31",{"name":41,"class":42},"Cedars-Sinai Medical Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":43},"100651536","phase-4-icosapent-ethyl-for-high-risk-coronary-plaques-assessed-by-18f-naf-petct-100651536","NCT07762755","Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET\u002FCT","A Randomized Controlled Trial Evaluating the Effect of Icosapent Ethyl on High-Risk Coronary Plaques Using 18F-Sodium Fluoride PET\u002FCT","IPE-NaF","Inclusion Criteria:\n\n* Male or female participants aged 18 to 75 years.\n* Ability to understand the study and provide written informed consent before enrollment.\n* Receiving a stable lipid-lowering regimen before enrollment, with the type and dose of statin therapy remaining unchanged for at least 4 weeks.\n* Fasting triglyceride level below 5.6 mmol\u002FL.\n* Presence of at least one of the following high-risk plaque features on coronary computed tomography angiography (CCTA):Pericoronary fat attenuation index greater than -70.1 Hounsfield units;\n* Low-attenuation plaque below 30 Hounsfield units;\n* Positive remodeling index greater than 1.1;\n* Spotty calcification;\n* or Napkin-ring sign, defined as a low-attenuation plaque core surrounded by a rim of higher attenuation.\n\nExclusion Criteria:\n\n* Current participation in another investigational drug, device, or procedure study, or receipt of an investigational drug or device within 4 weeks before enrollment.\n* Treatment with icosapent ethyl within 12 months before enrollment.\n* Known intolerance or hypersensitivity to icosapent ethyl or fish oil.\n* A previous diagnosis of homozygous familial hypercholesterolemia or hyperlipidemia requiring hemodialysis.\n* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, or stroke within 3 months before enrollment;\n* Planned cardiac surgery, percutaneous coronary intervention, or carotid artery stenting, or planned major noncardiac surgery during the study.\n* A known contraindication or limitation to PET\u002FCT, including exceeding scanner weight limits or having a device, carotid or aortic stent, or vascular graft that may cause imaging artifacts.\n* Autoimmune disease, vasculitis, or active inflammatory disease.\n* Serious infection within 1 month before enrollment or a current infection requiring intravenous antibiotic treatment.\n* Use within 6 weeks before enrollment or current use of medications that may significantly affect plaque inflammation, including oral, rectal, or injectable corticosteroids or immunosuppressive agents, such as cyclosporine, methotrexate, tacrolimus, azathioprine, antithymocyte globulin, sirolimus, anti-tumor necrosis factor agents such as infliximab, anti-interleukin-6 therapy such as tocilizumab, or anti-interleukin-1 therapy.\n* Use within 6 weeks before enrollment or current use of aspirin at a dose greater than 325 mg\u002Fday or nonsteroidal anti-inflammatory drugs at a dose greater than 1,000 mg\u002Fday.\n* Treatment within 12 months before enrollment with a cholesteryl ester transfer protein inhibitor, including anacetrapib, dalcetrapib, or evacetrapib, or with mipomersen or lomitapide.\n* Known clinically significant systemic disease, including hepatic, renal, hematologic, or malignant disease, or any other clinically significant comorbidity that may interfere with study participation or study assessments.\n* History of malignancy within the previous 5 years, except nonmelanoma skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, or stage I prostate cancer.\n* Inability or anticipated inability to complete all protocol-required visits or procedures, or any condition that may make the participant unreliable for study participation, including alcohol or other substance abuse within the previous year or a psychiatric disorder.\n* Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during study treatment or within 15 weeks after the last dose of study treatment.","75 Years",{"count":54,"type":21},100,[56],"PHASE4","This randomized controlled study will evaluate whether icosapent ethyl (IPE) can improve and stabilize high-risk coronary plaques in patients receiving stable low-density lipoprotein cholesterol (LDL-C)-lowering therapy. Potential participants will have coronary plaques identified by coronary computed tomography angiography (CCTA), with 30% to 70% narrowing in at least one major coronary artery and at least one high-risk plaque feature.\n\nAfter baseline imaging with fluorine-18 sodium fluoride positron emission tomography\u002Fcomputed tomography (18F-NaF PET\u002FCT), eligible participants will be randomly assigned in a 1:1 ratio to receive either IPE 2 g twice daily plus standard LDL-C-lowering therapy or standard LDL-C-lowering therapy alone for 12 months. At the end of treatment, participants will undergo repeat CCTA and 18F-NaF PET\u002FCT. Blood biomarkers and major adverse cardiovascular events will also be assessed during follow-up.",[59,60,61,27],"Coronary Artery Disease","Hyperlipidaemia","Hypertriglyceridaemia",[63,64,65,66,27,67,68,69,70,71,72,73],"Icosapent Ethyl","IPE","High-Risk Coronary Plaque","Coronary Plaque Stabilization","Intermediate Coronary Stenosis","18F-Sodium Fluoride PET\u002FCT","18F-NaF PET\u002FCT","Coronary Computed Tomography Angiography","CCTA","Coronary Microcalcification","Pericoronary Fat Attenuation Index","NOT_YET_RECRUITING","2026-08-11",{"date":77,"type":35},"2026-08-13",{"date":79,"type":21},"2026-08-01",{"date":81,"type":21},"2029-12-31",{"name":83,"class":84},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100629436","phase-3-a-study-of-bempedoic-acidezetimibehigh-intensity-statin-in-patients-without-cardiovascular-events-100629436","NCT07474649","A Study of Bempedoic Acid\u002FEzetimibe\u002FHigh-intensity Statin in Patients Without Cardiovascular Events","Effects of Bempedoic Acid\u002FEzetimibe\u002FHigh-intensity Statin on Plaque Regression and Stabilisation of Coronary Atherosclerosis Among Patients Without Cardiovascular Events","Inclusion Criteria:\n\nIn order to be eligible to participate in this trial, a potential participant must meet all of the following criteria:\n\n1. Age ≥18 years\n2. Having provided informed consent for participation in this trial\n3. Lipid-lowering treatment-naïve\n4. Presence of extensive coronary atherosclerosis meeting all of the criteria below:\n\n   * Unequivocal atherosclerosis in ≥5 American Heart Association (AHA) coronary segments (corresponding to a risk equivalent of obstructive coronary artery disease) and coronary artery disease - reporting and data system (CAD-RADS) category 1, 2, or 3\n   * Not expected to be a candidate for revascularisation during the duration of the trial\n   * Untreated LDL-C ≥2.6 mmol\u002FL and ≤4.5 mmol\u002FL (where a diet without pharmacological treatment is considered 'untreated')\n5. Able to provide informed consent\n\nExclusion Criteria:\n\nA potential participant who meets any of the following criteria will be excluded from participation in this trial:\n\n1. Known or suspected heterozygous or homozygous familial hypercholesterolaemia or familial combined hyperlipidaemia\n2. Known contraindication for BA, EZE, atorvastatin, and\u002For rosuvastatin. A participant with a contraindication for atorvastatin, can be assigned to triple therapy with rosuvastatin, and vice versa.\n3. Not expected to remain on a stable dose of high intensity triple therapy for the duration of the trial.\n4. History of myocardial infarction, stroke, or peripheral artery disease (PAD), and\u002For coronary revascularisation (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass grafting \\[CABG\\])\n5. Significant stenosis in the left main artery (≥50%) or proximal LAD artery (≥70%), or 3-vessel coronary artery disease (≥70% stenosis in major branches), clinically indicated for revascularisation\n6. Known significant liver disease (e.g., positive hepatitis B or hepatitis C serology) or significant hepatic dysfunction (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\] \\>3 x upper limit of normal \\[ULN\\])\n7. Known history of gout and\u002For uric acid levels at Screening ≥6.8 mg\u002FdL\n8. Known estimated glomerular filtration rate (eGFR) \\\u003C40 mL\u002Fmin\u002F1.73m² and\u002For receiving dialysis\n9. Active malignancy (not including non-melanoma skin cancer)\n10. Pregnant or breastfeeding\n11. Body mass index (BMI) \\>35 kg\u002Fm²\n12. Anticipated life expectancy \\\u003C52 weeks at the discretion of the local investigator\n13. Requiring emergent procedures or having any evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \\\u003C90 mmHg, severe congestive heart failure (New York Heart Association \\[NYHA\\] III or IV), or acute pulmonary oedema\n14. Suspicion of acute coronary syndrome (where acute myocardial infarction and unstable angina have not been ruled out)\n15. Complex congenital heart disease\n16. Known or suspected severe valvular heart disease or valvular heart disease anticipated to require intervention within 52 weeks at the discretion of the local investigator\n17. Cardiac arrythmia or tachycardia with significant likelihood of resulting in poor PCD-CTA image quality (especially atrial fibrillation or frequent premature beats)\n18. Intracoronary stents\n19. Prior pacemaker, internal defibrillator, or abandoned lead implantation\n20. Prosthetic heart valves\n21. Contraindications to contrast media or other medications needed for proper imaging (e.g., beta blockers and nitroglycerin)\n22. Use of any experimental or investigational drug within 40 days or 5 half-lives prior to Screening (whichever is longer), or parallel participation in another interventional study",{"count":93,"type":21},103,[95],"PHASE3","The overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin on changes in coronary plaque burden and plaque morphology in patients with coronary atherosclerosis without significant obstructive coronary artery disease and without prior history of an ischemic vascular event.",[27,98,99],"Mixed Dyslipidemia","Hypercholesterolemia",[101,102,103,104,105,106,107],"Coronary atherosclerosis","Primary non-familial hypercholesterolaemia","Mixed dyslipidaemia","Bempedoic acid","Ezetimibe","Atorvastatin","Rosuvastatin","2026-08-04",{"date":110,"type":35},"2026-08-07",{"date":112,"type":21},"2026-08-15",{"date":114,"type":21},"2028-10-02",{"name":116,"class":117},"Daiichi Sankyo","INDUSTRY",12,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":43},"100579985","using-cta-measures-to-define-cardiac-risk-in-nfl-alumni-100579985","NCT06831409","Using CTA Measures to Define Cardiac Risk In NFL Alumni","GAMEFILM","Inclusion Criteria:\n\n* Retired NFL player\n\nExclusion Criteria:\n\n* CCTA not successfully processed for FFRct and AI-Plaque",{"count":127,"type":21},300,"OBSERVATIONAL","The GAMEFILM Registry is a post-market, multi-center, data collection study assessing the presence of CAD in NFL alumni.",[131,132,27],"Coronary Artery Disease (CAD)","Heart Disease",[134,132],"NFL","2025-08-25",{"date":137,"type":35},"2025-08-26",{"date":139,"type":35},"2024-12-17",{"date":141,"type":21},"2026-12-31",{"name":143,"class":117},"HeartFlow, Inc.",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":43},"100490028","effects-of-switching-from-cigarettes-to-tobacco-heating-system-on-coronary-atherosclerosis-progression-100490028","NCT05660798","Effects of Switching From Cigarettes to Tobacco Heating System on Coronary Atherosclerosis Progression","Effects of Switching From Cigarettes to Tobacco Heating System on Coronary Atherosclerosis Progression in Patients With Stable Coronary Artery Disease","SWITCH","Inclusion Criteria:\n\n1. Adults aged \\>18 years and \\\u003C75 years\n2. Subjects with stable chronic coronary syndrome defined as the presence of at least one coronary artery stenosis \\>=20% due to coronary plaque visible on coronary computed tomography angiography (CCTA), in an artery with a reference diameter \\> 2.0mm\n3. History of smoking pack-years ≥10 (Pack-years will be calculated by taking the average number of cigarettes smoked per day divided by 20 and multiplied by the number of years smoked), based on self-reporting\n4. Current smokers with a minimum of self-reported current smoking pattern of \\>10 cigarettes\u002Fday during the last 6 months prior to screening, smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng\u002FmL)\n5. Patients that have been advised to quit smoking and informed of a smoking risk and cessation programs (per local SOC) and who are still not willing to set a quit date within the next 30 days at screening\n6. Stable treatment for coronary atherosclerosis according to the guidelines\n7. Have understood the study and have signed informed consent\n\nExclusion Criteria:\n\n1. Any acute cardiovascular event (i.e. ACS, MI, Stroke, TIA, Limb ischemia), unstable angina or revascularization within 30 days prior to screening\n2. Planned coronary intervention (PCI, CABG) at screening\n3. Previous CABG\n4. Preexisting heart failure with reduced ejection fraction (EF \\\u003C50%)\n5. Severe uncontrolled hypertension (at the discretion of investigator)\n6. Diabetes\n7. Subjects with documented genetic familial hypercholesterolemia\n8. Subjects have known serious infection or chronic inflammatory systemic disease (e.g. rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis)\n9. Subjects have a known non-cardiovascular disease that is associated with poor prognosis (e.g. metastatic cancer)\n10. Patient with currently active cancer or history of cancer within the last 5 years\n11. Subjects have hypersensitivity or any other warnings listed in the local labeling for THS\n12. Subjects have hypersensitivity to imaging iodine contrast agents\n13. GFR\\\u003C45 ml\u002Fmin\u002F1,73 m2\n14. Subjects who could not participate for any reason other than medical (e.g., psychological and\u002For social reason) per Investigator's judgment\n15. Subjects have any other clinical condition that would jeopardize the subject's safety while participating in this study, per Investigator's judgment\n16. Female subject is pregnant or breast-feeding, or planning to become pregnant during the study\n17. Subjects have previously participated in this study, or in an interventional study (drug or medical device) within 30 days of screening (participation in observational studies\u002Fregistries allowed)\n18. Subjects have a close affiliation with the investigational site: a close relative of the investigator, a person dependent on the investigational site (e.g. employee or student of the investigational site)\n19. Subjects are current or former employee of the tobacco industry or their first-degree relatives (parent, child, spouse)",{"count":153,"type":21},180,[24],"Objective:\n\nTo evaluate the impact of heated versus combustion tobacco products on progression of atherosclerosis in patients with CAD unable(unwilling) to quit smoking.\n\nRationale:\n\nDespite the efforts to curb smoking and full awareness of its deleterious health impact, smoking remains a significant contributor to morbidity and mortality. Some health impact of smoking may be improved by other forms of cigarettes than traditional combustion, especially for subjects unwilling or unable to stop smoking. As recently as 2020, one of heated tobacco products (HTP)(IQOS) was FDA Authorized as a 'Reduced Exposure' product. The available evidence to date allows to conclude that the IQOS system heats tobacco but does not burn it, which significantly reduces the production of harmful and potentially harmful chemicals. Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduced body's exposure to harmful or potentially harmful chemicals. There is also evidence indicating lower levels of inflammatory markers and improved vascular function associated with use of heated tobacco products. However, it is unknown whether the reduction in the exposure translates into potential reduction of harm within cardiovascular system, as compared to the traditional (combustion) cigarettes.\n\nThe evidence is of crucial importance for patients with cardiovascular diseases, medical community, and national health authorities planning evidence based policies regarding HTP\u002Fcigarettes.",[59,27,157],"Nicotine Dependence","2024-12-16",{"date":160,"type":35},"2024-12-19",{"date":162,"type":35},"2023-02-09",{"date":164,"type":21},"2025-12-31",{"name":166,"class":42},"National Institute of Cardiology, Warsaw, Poland"]